Neurocrine Biosciences Reports P-III (CAHtalyst) Pediatric Study Results of Crinecerfont in Children and Adolescents for Congenital Adrenal Hyperplasia
Shots:
- The P-III pediatric study evaluating crinecerfont (selective corticotropin-releasing factor type 1 receptor antagonist) vs PBO in children & adolescents aged 2–17yrs. with CAH due to 21-hydroxylase deficiency
- The trial met its 1EPs & showed a reduction from baseline in serum androstenedione from baseline at 4wk. vs PBO following a glucocorticoid (GC) stable period. The 2EPs showed a reduction from baseline in daily glucocorticoid dose while maintaining androgen control (30% vs 0%), was well-tolerated
- The study also met the other 2EPs & showed a reduction in serum 17-hydroxyprogesterone from baseline at 4wk. The (CAHtalyst) pediatric & adult studies results incl. data from the open-label treatment periods will support regulatory submissions to the US FDA in 2024
Ref: PRNewswire | Image: Neurocrine
Related News:- Neurocrine Biosciences Reports P-III Study (CAHtalyst) Results of Crinecerfont for Congenital Adrenal Hyperplasia in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
